These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15607121)

  • 1. Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options.
    Rogers DF
    Pulm Pharmacol Ther; 2005; 18(1):1-8. PubMed ID: 15607121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD.
    Hanania NA
    Pulm Pharmacol Ther; 2008; 21(3):540-50. PubMed ID: 18280761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The airway pathophysiology of COPD: implications for treatment.
    Rodríguez-Roisin R
    COPD; 2005 Jun; 2(2):253-62. PubMed ID: 17136952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD.
    Ohar JA; Donohue JF
    Semin Respir Crit Care Med; 2010 Jun; 31(3):321-33. PubMed ID: 20496301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society.
    Qaseem A; Wilt TJ; Weinberger SE; Hanania NA; Criner G; van der Molen T; Marciniuk DD; Denberg T; Schünemann H; Wedzicha W; MacDonald R; Shekelle P; ; ; ;
    Ann Intern Med; 2011 Aug; 155(3):179-91. PubMed ID: 21810710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators.
    Hanania NA; Donohue JF
    Proc Am Thorac Soc; 2007 Oct; 4(7):526-34. PubMed ID: 17878465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled adrenergics and anticholinergics in obstructive lung disease: do they enhance mucociliary clearance?
    Restrepo RD
    Respir Care; 2007 Sep; 52(9):1159-73; discussion 1173-5. PubMed ID: 17716384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COPD, a multicomponent disease: implications for management.
    Agusti AG
    Respir Med; 2005 Jun; 99(6):670-82. PubMed ID: 15878483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology and therapeutics of bronchodilators.
    Cazzola M; Page CP; Calzetta L; Matera MG
    Pharmacol Rev; 2012 Jul; 64(3):450-504. PubMed ID: 22611179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tiotropium and other long acting bronchodilators in chronic obstructive pulmonary disease.
    Currie GP; Rossiter C; Miles SA; Lee DK; Dempsey OJ
    Pulm Pharmacol Ther; 2006; 19(2):112-9. PubMed ID: 15970450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.
    Beeh KM; Beier J
    Adv Ther; 2010 Mar; 27(3):150-9. PubMed ID: 20411368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.
    Cazzola M; Molimard M
    Pulm Pharmacol Ther; 2010 Aug; 23(4):257-67. PubMed ID: 20381630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of inhaled long-acting β-agonist and anticholinergic effectiveness in older patients with chronic obstructive pulmonary disease: a cohort study.
    Gershon A; Croxford R; To T; Stanbrook MB; Upshur R; Sanchez-Romeu P; Stukel T
    Ann Intern Med; 2011 May; 154(9):583-92. PubMed ID: 21536937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes.
    Hanania NA
    Clin Ther; 2007 Oct; 29(10):2121-33. PubMed ID: 18042470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple therapy for the management of COPD: a review.
    Gaebel K; McIvor RA; Xie F; Blackhouse G; Robertson D; Assasi N; Hernandez P; Goeree R
    COPD; 2011 Jun; 8(3):206-43. PubMed ID: 21513437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common lung conditions: chronic obstructive pulmonary disease.
    Delzell JE
    FP Essent; 2013 Jun; 409():23-31. PubMed ID: 23767419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can β2-adrenoceptor agonists, anticholinergic drugs, and theophylline contribute to the control of pulmonary inflammation and emphysema in COPD?
    Zhang WH; Zhang Y; Cui YY; Rong WF; Cambier C; Devillier P; Bureau F; Advenier C; Gustin P
    Fundam Clin Pharmacol; 2012 Feb; 26(1):118-34. PubMed ID: 22044554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of inhaled therapy on biomarkers of systemic inflammation in stable chronic obstructive pulmonary disease.
    Antoniu SA
    Biomarkers; 2010 Mar; 15(2):97-103. PubMed ID: 19929747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease?
    Salama RO; Young PM; Rogueda P; Lallement A; Iliev I; Traini D
    Expert Opin Pharmacother; 2011 Aug; 12(12):1913-32. PubMed ID: 21714776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting bronchodilator therapy for the treatment of chronic obstructive pulmonary disease.
    Chen AM; Bollmeier SG; Finnegan PM
    Ann Pharmacother; 2008 Dec; 42(12):1832-42. PubMed ID: 18957624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.